



CEOcast, Inc.
Dan Schustack
Investor Relations
Tel: (212) 732-4300
Email: DSchustack@ceocast.com

ImmunoCellular Therapeutics to Present at the 13th Annual BIO CEO & Investor Conference

LOS ANGELES, CA – February 11, 2011 – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that Manish Singh, Ph.D., the company's chief executive officer, will deliver a corporate overview at the upcoming 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. Dr. Singh's presentation will take place on Monday, February 14, 2011 at 2:30 p.m. on the 4th Floor.

A webcast of the presentation will be available one hour after the presentation at <http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm> and will be accessible until May 16, 2011.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials during the first half of 2011. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to complete the Phase II trial for ICT-107 and to fund development of other product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials; the risk of delays in enrolling patients for, or other delays in completing, the Phase II trial for ICT-107; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or cancer stem cell vaccine or that any patents covering those vaccines will provide commercially significant protection for these technologies. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.